Focus Partners Wealth Takes Position in Prestige Consumer Healthcare Inc. (NYSE:PBH)

Focus Partners Wealth acquired a new stake in Prestige Consumer Healthcare Inc. (NYSE:PBH - Free Report) during the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund acquired 3,015 shares of the company's stock, valued at approximately $235,000.

Other large investors also recently bought and sold shares of the company. Kayne Anderson Rudnick Investment Management LLC purchased a new stake in shares of Prestige Consumer Healthcare in the fourth quarter valued at about $84,932,000. Raymond James Financial Inc. acquired a new stake in Prestige Consumer Healthcare in the fourth quarter valued at about $42,593,000. Norges Bank acquired a new position in Prestige Consumer Healthcare during the 4th quarter worth approximately $40,009,000. Bessemer Group Inc. increased its position in Prestige Consumer Healthcare by 10,053.1% during the 4th quarter. Bessemer Group Inc. now owns 295,050 shares of the company's stock worth $23,041,000 after purchasing an additional 292,144 shares during the period. Finally, Boston Trust Walden Corp raised its stake in shares of Prestige Consumer Healthcare by 43.5% during the 4th quarter. Boston Trust Walden Corp now owns 831,627 shares of the company's stock worth $64,942,000 after buying an additional 252,089 shares in the last quarter. Hedge funds and other institutional investors own 99.95% of the company's stock.

Wall Street Analyst Weigh In

A number of analysts recently weighed in on the company. Oppenheimer lifted their price target on Prestige Consumer Healthcare from $87.00 to $93.00 and gave the company an "outperform" rating in a research note on Thursday, February 13th. DA Davidson upped their target price on shares of Prestige Consumer Healthcare from $95.00 to $104.00 and gave the stock a "buy" rating in a research report on Friday, February 7th. Royal Bank of Canada raised shares of Prestige Consumer Healthcare to a "hold" rating in a report on Thursday, May 8th. Wall Street Zen raised Prestige Consumer Healthcare from a "hold" rating to a "buy" rating in a research note on Saturday, May 17th. Finally, Canaccord Genuity Group lifted their price objective on Prestige Consumer Healthcare from $93.00 to $100.00 and gave the stock a "buy" rating in a report on Friday, February 7th. Three investment analysts have rated the stock with a hold rating and four have assigned a buy rating to the company. According to data from MarketBeat, Prestige Consumer Healthcare presently has an average rating of "Moderate Buy" and an average target price of $93.33.

Prestige Consumer Healthcare Price Performance

Shares of Prestige Consumer Healthcare stock traded down $1.06 during trading on Wednesday, hitting $84.83. 32,109 shares of the company were exchanged, compared to its average volume of 296,826. Prestige Consumer Healthcare Inc. has a fifty-two week low of $62.35 and a fifty-two week high of $90.04. The company has a quick ratio of 2.20, a current ratio of 3.68 and a debt-to-equity ratio of 0.56. The firm has a 50 day moving average price of $83.59 and a 200 day moving average price of $82.36. The stock has a market capitalization of $4.19 billion, a price-to-earnings ratio of 19.87, a P/E/G ratio of 2.69 and a beta of 0.44.

Prestige Consumer Healthcare (NYSE:PBH - Get Free Report) last released its quarterly earnings results on Thursday, May 8th. The company reported $1.32 earnings per share for the quarter, topping analysts' consensus estimates of $1.30 by $0.02. The company had revenue of $296.52 million during the quarter, compared to analysts' expectations of $289.36 million. Prestige Consumer Healthcare had a return on equity of 12.36% and a net margin of 19.13%. The business's revenue for the quarter was up 7.0% compared to the same quarter last year. During the same period in the previous year, the firm posted $1.02 earnings per share. On average, equities analysts expect that Prestige Consumer Healthcare Inc. will post 4.5 earnings per share for the current fiscal year.

Insiders Place Their Bets

In other Prestige Consumer Healthcare news, SVP Mary Beth Fritz sold 1,678 shares of the business's stock in a transaction on Monday, March 10th. The stock was sold at an average price of $90.00, for a total value of $151,020.00. Following the completion of the transaction, the senior vice president now directly owns 17,157 shares in the company, valued at approximately $1,544,130. The trade was a 8.91% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. 1.60% of the stock is owned by corporate insiders.

Prestige Consumer Healthcare Profile

Prestige Consumer Healthcare Inc, together with its subsidiaries, develops, manufactures, markets, distributes, and sells over-the-counter (OTC) health and personal care products in the United States and internationally. The company operates in two segments, North American OTC Healthcare and International OTC Healthcare.